119,00 €
0,06 % heute
L&S, 7. Oktober, 07:33 Uhr
ISIN
US64125C1099
Symbol
NBIX
Berichte

Neurocrine Biosciences, Inc. Aktie News

Neutral
PRNewsWire
etwa 10 Stunden alt
SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marke...
Neutral
PRNewsWire
etwa 17 Stunden alt
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders®  SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an establis...
Neutral
PRNewsWire
14 Tage alt
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.
Neutral
PRNewsWire
15 Tage alt
SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845).
Neutral
Seeking Alpha
19 Tage alt
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Todd Tushla Conference Call Participants Philip Nadeau - TD Cowen, Research Division Presentation Philip Nadeau TD Cowen, Research Division Good afternoon, an...
Neutral
PRNewsWire
20 Tage alt
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych C...
Neutral
Seeking Alpha
28 Tage alt
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welc...
Neutral
Seeking Alpha
etwa ein Monat alt
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst Now we're ready to get st...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen